<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Allogeneic hematopoietic cell transplantation in follicular lymphoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Allogeneic hematopoietic cell transplantation in follicular lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Allogeneic hematopoietic cell transplantation in follicular lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan W Friedberg, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 25, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H95432057"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma (NHL). It is the most common of the indolent NHLs defined as those lymphomas in which survival of the untreated patient is measured in years. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a>.)</p><p>The initial treatment of FL depends upon the stage of disease at presentation. Patients with early stage disease may be cured with radiation therapy, while patients with advanced stage disease are initially managed with an immunotherapy-based regimen (eg, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus chemotherapy). The use of either autologous or allogeneic hematopoietic cell transplantation (HCT) in FL is controversial. When applied to a highly selected patient population, autologous HCT results in a disease-free survival at 10 years of approximately 40 percent and has a low treatment-related mortality rate. In comparison, allogeneic HCT may cure a higher percentage of patients with advanced stage FL, but is associated with substantial treatment-related mortality.</p><p>The use of allogeneic HCT, however, is limited since even ideal candidates who undergo allogeneic HCT have a high rate of treatment-related mortality, its efficacy compared with autologous HCT is not fully established, and non-transplant treatment options have expanded over recent decades. In addition, chimeric antigen receptor modified T cell therapy is being studied in patients with FL and may replace allogeneic HCT for a subset of patients.</p><p>The use of allogeneic HCT in FL is reviewed below. The use of autologous HCT in FL and comparison with other treatment options are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4709.html" rel="external">"Autologous hematopoietic cell transplantation in follicular lymphoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4755.html" rel="external">"Treatment of relapsed or refractory follicular lymphoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4718.html" rel="external">"Primary cutaneous follicle center lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H95432426"><span class="h1">TIMING OF TRANSPLANT</span><span class="headingEndMark"> — </span>The ideal timing of HCT in FL is unknown and controversial. Ideally, allogeneic HCT should be performed within the context of a clinical trial. However, attempts to conduct randomized trials in this setting have failed. Outside of a clinical trial, HCT is reserved for patients with relapsed or refractory FL or for those with histologic transformation to a more aggressive histology. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4755.html" rel="external">"Treatment of relapsed or refractory follicular lymphoma", section on 'Autologous transplant for eligible patients'</a>.)</p><p class="headingAnchor" id="H221671"><span class="h1">DETERMINING TRANSPLANT ELIGIBILITY</span><span class="headingEndMark"> — </span>The determination of transplant eligibility should be made based on a risk-benefit assessment, and the needs and wishes of the patient. Eligibility for HCT varies across countries and institutions and depends on the type of transplantation (ie, allogeneic versus autologous) and the conditioning regimen (eg, myeloablative versus nonmyeloablative).</p><p>In most centers in the United States, patients are considered eligible for nonmyeloablative allogeneic HCT if they are less than 70 years of age, with normal cardiac, liver, and renal function, and have a good performance status (ECOG performance status 0 or 1). For myeloablative allogeneic transplantation, eligibility is more restrictive in that patients should typically be less than 55 years of age.</p><p>A more detailed discussion of transplant eligibility is presented separately. (See  <a class="medical medical_review" href="/z/d/html/16870.html" rel="external">"Determining eligibility for allogeneic hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H222242"><span class="h1">DONOR SELECTION</span><span class="headingEndMark"> — </span>The preferred donor for patients undergoing allogeneic HCT for FL is an HLA-matched sibling or matched unrelated donor (MUD). However, fewer than 25 percent of patients in the transplantable age group have an HLA-matched sibling donor. Allogeneic HCT using a partially matched family member donor or umbilical cord blood may be considered for patients who do not have an HLA-identical matched donor. (See  <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/3537.html" rel="external">"Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"</a>.)</p><p class="headingAnchor" id="H95432958"><span class="h1">PREPARATIVE REGIMEN</span></p><p class="headingAnchor" id="H222791"><span class="h2">Regimen intensity definitions</span><span class="headingEndMark"> — </span>Preparative regimens are generally divided into three categories: myeloablative, nonmyeloablative, and reduced-intensity regimens. (See  <a class="medical medical_review" href="/z/d/html/3557.html" rel="external">"Preparative regimens for hematopoietic cell transplantation", section on 'Definitions'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Myeloablative regimens – A myeloablative regimen consists of a single agent or combination of agents expected to destroy the hematopoietic cells in the bone marrow, and results in profound pancytopenia within one to three weeks from the time of administration. The resulting pancytopenia is long-lasting, usually irreversible, and in most instances fatal unless hematopoiesis is restored by infusion of hematopoietic stem cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonmyeloablative regimens – A nonmyeloablative regimen is one that will cause minimal cytopenia (but significant lymphopenia) by itself and does not require stem cell support. However, the transplant, when given in this setting, usually becomes myeloablative because the engrafting donor T cells will eventually eliminate host hematopoietic cells, allowing the establishment of donor hematopoiesis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced intensity regimens – Reduced intensity regimens are an intermediate category of regimens that do not fit the definition of myeloablative or nonmyeloablative. Such regimens cause cytopenias, which may be prolonged and result in significant morbidity and mortality, and require hematopoietic stem cell support.</p><p></p><p>Nonmyeloablative and reduced intensity preparative regimens rely more on donor cellular immune effects and less on the cytotoxic effects of the preparative regimen to control the underlying disease.</p><p class="headingAnchor" id="H1044876790"><span class="h2">Choice of regimen</span><span class="headingEndMark"> — </span>A nonmyeloablative or reduced intensity preparative regimen is used for most patients with FL undergoing allogeneic HCT [<a href="#rid1">1</a>]. The choice of regimen for an individual patient must take into account the patient's age and comorbidities, the behavior of the disease, and the depth of response at the time of transplant.</p><p>Nonmyeloablative, reduced intensity, and myeloablative regimens all appear to have a survival benefit for the treatment of relapsed FL, but differing risks. Nonrandomized comparisons suggest that, when compared with myeloablative regimens, nonmyeloablative and reduced intensity regimens are associated with lower treatment-related mortality and a higher risk of relapse [<a href="#rid1">1-5</a>]. However, a comparison of nonrandomized trials of these different procedures is limited by the use of different patient selection criteria for the different regimens [<a href="#rid6">6</a>]. Unfortunately, a randomized trial is difficult to perform in this circumstance.</p><p>Nonmyeloablative and reduced intensity regimens are preferred for most patients, especially older patients and those with comorbidities, those who are in complete remission at the time of transplant, and those who relapse after autologous HCT. Myeloablative allogeneic HCT is associated with greater treatment-related mortality and most patients will not be candidates for this approach [<a href="#rid7">7-10</a>]. Myeloablative regimens are typically reserved for young, highly motivated patients with highly aggressive FL.</p><p class="headingAnchor" id="H4237101970"><span class="h1">EFFICACY AND TOXICITY</span></p><p class="headingAnchor" id="H3906163027"><span class="h2">Allogeneic transplant overall</span><span class="headingEndMark"> — </span>When compared with autologous HCT, allogeneic HCT is associated with a higher treatment-related mortality, but also with a lower relapse rate and greater potential for cure. Allogeneic HCT is associated with mortality from both short-term (eg, graft-versus-host disease [GVHD], infection) and long-term (eg, myelodysplastic syndrome, acute myeloid leukemia, other secondary malignancies) transplant-related complications.</p><p>Even with nonmyeloablative or reduced intensity allogeneic HCT, the treatment-related mortality at two to three years ranges from 15 to 25 percent and largely reflects deaths from GVHD and infectious complications [<a href="#rid2">2,11</a>]. Moreover, the cumulative incidence of GVHD (especially chronic GVHD) is consistently above 50 percent [<a href="#rid2">2,11-13</a>]. Despite this toxicity, single-institution series and registry studies have reported progression-free survival rates at three to five years of 45 to 85 percent [<a href="#rid2">2,11-15</a>].</p><p>A combined analysis of data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and European Society for Blood and Marrow Transplantation (EBMT) evaluated the outcomes of 1567 patients with relapsed or refractory FL who underwent allogeneic HCT from 2001 to 2011 with an HLA-matched related or unrelated donor [<a href="#rid1">1</a>]. Patients with transformed FL and those undergoing a planned tandem HCT were excluded. A nonmyeloablative or reduced intensity preparative regimen was used in 77 percent. After a median follow-up of 55 months, the following estimated five-year outcomes were reported:</p><p class="bulletIndent1"><span class="glyph">●</span>Overall survival – 61 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Progression-free survival – 52 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Relapse or progression – 19 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment-related mortality – 29 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Acute GVHD grade 2 to 4 – 20 percent at day 100</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic GVHD – 45 percent at one year</p><p></p><p>Predictors of worse outcome included older age, &gt;3 prior lines of therapy, chemotherapy-resistant disease, and impaired performance status.</p><p class="headingAnchor" id="H95433400"><span class="h2">Nonmyeloablative and reduced intensity HCT</span><span class="headingEndMark"> — </span>A nonmyeloablative or reduced intensity preparative regimen is used for most patients with FL undergoing allogeneic HCT [<a href="#rid1">1</a>]. Nonmyeloablative allogeneic HCT and reduced intensity HCT are associated with lower rates of treatment-related toxicity and treatment-related mortality, but higher rates of relapse compared with rates previously seen with myeloablative allogeneic transplantation.</p><p>Nonmyeloablative and reduced intensity conditioning regimens have extended the eligibility of allogeneic HCT to older patients and those with comorbidities [<a href="#rid16">16-23</a>]. Even for patients who have relapsed after autologous HCT, nonmyeloablative or reduced intensity conditioning allogeneic HCT affords the possibility of prolonged disease-free survival. The reported rates of progression-free survival after nonmyeloablative allogeneic HCT vary, but are reliably above 40 percent (and mostly around 60 percent) at two to three years [<a href="#rid1">1,12,17,22-26</a>]. In these series, there is also convincing evidence for a plateau in the progression-free survival curves suggesting that nonmyeloablative allogeneic HCT has curative potential. Specific regimens used for nonmyeloablative allogeneic HCT are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3557.html" rel="external">"Preparative regimens for hematopoietic cell transplantation", section on 'NMA and RIC regimens'</a>.)</p><p>The following is a survey of studies that have reported on the use of nonmyeloablative allogeneic HCT in patients with FL:</p><p class="bulletIndent1"><span class="glyph">●</span>The longest experience is from a prospective trial of nonmyeloablative HCT in 47 patients with chemotherapy-sensitive relapsed FL given a preparative regimen of <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid11">11</a>]. The two patients with a matched unrelated donor were also given equine antithymocyte globulin prior to the graft infusion. GVHD prophylaxis consisted of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. Acute GVHD was seen in 11 percent of patients. At a median follow-up of 107 months, the estimated rates of overall and progression-free survival at 11 years were 78 and 72 percent, respectively [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another prospective trial, the same investigators treated 26 patients with relapsed or refractory (10 patients) FL with <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <sup>90</sup>Y-ibritumomab tiuxetan followed by allogeneic HCT from a 5 or 6 of 6 HLA-matched donor [<a href="#rid27">27</a>]. At a median follow-up of 33 months, the estimated rates of progression-free and overall survival at three years were 85 and 88 percent, respectively. Similar outcomes were seen in patients with chemotherapy-sensitive and chemotherapy-refractory disease at the time of enrollment. The three-year cumulative incidence of chronic GVHD was 39 percent (24 percent extensive).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study of nonmyeloablative allogeneic HCT involved 188 patients, including 52 previously treated patients with indolent non-Hodgkin lymphoma (NHL), 85 percent of whom had chemosensitive disease; 29 percent had received a prior autologous HCT [<a href="#rid18">18</a>]. Nonmyeloablative allogeneic HCT yielded a 100-day treatment-related mortality of 11 percent, and an estimated two-year overall survival rate of 65 percent. Predictors for an adverse outcome included chemotherapy-resistant disease and age &gt;50 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective review of total body irradiation with or without <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a> followed by allogeneic HCT in 62 patients with chemotherapy-refractory indolent (75 percent) or transformed NHL reported three-year estimated overall and progression-free survival rates of 52 and 43 percent, respectively [<a href="#rid12">12</a>]. Patients with indolent disease and related donors had even higher overall and progression-free survival rates of 67 and 54 percent, respectively. Treatment was well tolerated. Long-term complications were limited. Survivors had a median Karnofsky performance status rating of 85 percent  (<a class="graphic graphic_table graphicRef58785" href="/z/d/graphic/58785.html" rel="external">table 1</a>). Approximately half of patients suffered from extensive chronic GVHD.</p><p></p><p class="headingAnchor" id="H95433425"><span class="h2">Myeloablative HCT</span><span class="headingEndMark"> — </span>Myeloablative preparative regimens are used in a minority of patients undergoing allogeneic HCT for FL. They are generally reserved for young, highly motivated patients with highly aggressive FL. When compared with autologous HCT, myeloablative allogeneic HCT results in lower relapse rates but a higher treatment-related mortality of approximately 30 percent [<a href="#rid15">15,28-30</a>]. These differences were highlighted in a report from the International Bone Marrow Transplant Registry [<a href="#rid29">29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In 176 patients with FL, 67 percent of whom had chemotherapy-sensitive disease at the time of HCT, estimated treatment-related mortality, recurrence rates, and overall survival at five years following allogeneic HCT were 30, 21, and 51 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During this same period of time, 597 patients with FL received unpurged autologous HCT; 82 percent were chemotherapy sensitive at the time of transplant. Estimated treatment-related mortality, recurrence rates, and overall survival at five years following unpurged autologous HCT were 8, 58, and 55 percent, respectively.</p><p></p><p class="headingAnchor" id="H95434096"><span class="h1">CARE DURING THE TRANSPLANTATION</span><span class="headingEndMark"> — </span>Allogeneic HCT is largely reserved for the inpatient setting. Engraftment takes longer than it does for autologous HCT, and infections are more common. Virtually all patients require blood product support in the form of red blood cell and platelet transfusions until the transplanted marrow cells engraft sufficiently to support hematopoiesis. (See  <a class="medical medical_review" href="/z/d/html/3538.html" rel="external">"Hematopoietic support after hematopoietic cell transplantation"</a>.)</p><p>Patients who undergo HCT are at risk for bacterial, viral, and fungal infections, the time course of which varies in the post-transplant period, according to the degree of immune deficiency and cytopenia induced by the transplantation procedure  (<a class="graphic graphic_figure graphicRef64491" href="/z/d/graphic/64491.html" rel="external">figure 1</a>). Prophylactic therapies to prevent infection, including antiviral and antifungal drugs, are recommended during a period of increased risk. In addition, all markers of potential infection must be investigated thoroughly. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1397.html" rel="external">"Prevention of infections in hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a>.)</p><p class="headingAnchor" id="H223137"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Patients are seen at periodic intervals to assess for progression. Our approach parallels that which we use after initial treatment. This is presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma", section on 'Surveillance for relapse'</a>.)</p><p>Allogeneic transplant recipients are at risk of developing therapy-related complications that may present years after treatment. These complications have surfaced as significant causes of increased mortality. Our approach to the ongoing evaluation of the long-term HCT survivor is presented separately. (See  <a class="medical medical_review" href="/z/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor"</a>.)</p><p class="headingAnchor" id="H221821"><span class="h1">TREATMENT OF RELAPSE AFTER HCT</span><span class="headingEndMark"> — </span>Treatment options for relapsed FL after an allogeneic HCT include reduction of immunosuppression, donor lymphocyte infusion (DLI), and treatment with salvage chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/4755.html" rel="external">"Treatment of relapsed or refractory follicular lymphoma"</a>.)</p><p>Both withdrawal of immunosuppression and DLI harness the graft-versus-tumor effect and have demonstrated clinical benefit in many patients with FL relapsing after allogeneic HCT [<a href="#rid31">31-33</a>]. Predictive factors for response to DLI are remission before HCT and the occurrence of acute or chronic graft-versus-host disease. DLI has been complicated by graft-versus-host disease in a substantial percentage of patients and in some instances graft failure. Thus, the optimal dose and schedule of DLI continue to be explored. (See  <a class="medical medical_review" href="/z/d/html/3552.html" rel="external">"Immunotherapy for the prevention and treatment of relapse following allogeneic hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H2471238816"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/133193.html" rel="external">"Society guideline links: Management of follicular lymphoma"</a>.)</p><p class="headingAnchor" id="H95434268"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/117867.html" rel="external">"Patient education: Allogeneic bone marrow transplant (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/694.html" rel="external">"Patient education: Follicular lymphoma in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/686.html" rel="external">"Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H95434275"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role in therapy</strong> – The use of hematopoietic cell transplantation (HCT) in follicular lymphoma (FL) is controversial.</p><p></p><p class="bulletIndent1">HCT is generally reserved for patients with relapsed or refractory FL or for those with histologic transformation to a more aggressive histology, each in the setting of chemotherapy-sensitive disease. While allogeneic HCT may rescue some patients with chemotherapy-refractory disease, the outcomes are clearly inferior in this setting. (See <a class="local">'Timing of transplant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determining HCT eligibility</strong> – To be eligible for HCT, the patient must have normal cardiac, liver, and renal function, and have a good performance status. In most centers in the United States, patients are considered eligible for nonmyeloablative allogeneic HCT if they are less than 70 years of age. For myeloablative allogeneic transplantation, patients should typically be less than 55 years of age. (See  <a class="medical medical_review" href="/z/d/html/4709.html" rel="external">"Autologous hematopoietic cell transplantation in follicular lymphoma", section on 'Determining transplant eligibility'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comparison with other therapies</strong> – The decision of whether to proceed with transplantation should be based on the patient's preference, condition, and the expected disease course. For the latter, there is no definitive score or metric. A choice among therapies for patients with relapsed FL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4755.html" rel="external">"Treatment of relapsed or refractory follicular lymphoma"</a>.)</p><p></p><p class="bulletIndent1">The use of allogeneic HCT is limited since even ideal candidates who undergo allogeneic HCT have a high rate of treatment-related mortality and nontransplant treatment options have expanded over recent decades. In addition, chimeric antigen receptor modified T cell therapy is an option for patients with FL after two or more lines of therapy and may replace allogeneic HCT for a subset of patients. </p><p></p><p class="bulletIndent1">When compared with autologous HCT, allogeneic HCT is associated with a higher treatment-related mortality rate (15 to 25 percent), but a higher potential rate of cure (50 to 60 percent). A nonmyeloablative or reduced intensity preparative regimen is used for most patients with FL undergoing allogeneic HCT. (See <a class="local">'Nonmyeloablative and reduced intensity HCT'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse after HCT</strong> – Treatment options for relapsed FL after an allogeneic HCT include reduction of immunosuppression, donor lymphocyte infusion, and treatment with salvage chemotherapy. (See <a class="local">'Treatment of relapse after HCT'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sureda A, Zhang MJ, Dreger P, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer 2018; 124:1733.</a></li><li><a class="nounderline abstract_t">Hari P, Carreras J, Zhang MJ, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14:236.</a></li><li><a class="nounderline abstract_t">Tomblyn M, Brunstein C, Burns LJ, et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14:538.</a></li><li><a class="nounderline abstract_t">Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12:1326.</a></li><li><a class="nounderline abstract_t">Sorror ML, Storer BE, Maloney DG, et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111:446.</a></li><li><a class="nounderline abstract_t">Oliansky DM, Gordon LI, King J, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2010; 16:443.</a></li><li><a class="nounderline abstract_t">van Besien KW, Khouri IF, Giralt SA, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 1995; 13:1096.</a></li><li><a class="nounderline abstract_t">Kim SW, Tanimoto TE, Hirabayashi N, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 2006; 108:382.</a></li><li><a class="nounderline abstract_t">Ingram W, Devereux S, Das-Gupta EP, et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol 2008; 141:235.</a></li><li><a class="nounderline abstract_t">Villa D, Crump M, Panzarella T, et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol 2013; 31:1164.</a></li><li><a class="nounderline abstract_t">Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111:5530.</a></li><li><a class="nounderline abstract_t">Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:211.</a></li><li><a class="nounderline abstract_t">Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14:418.</a></li><li><a class="nounderline abstract_t">Kuruvilla J, Pond G, Tsang R, et al. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma. Biol Blood Marrow Transplant 2008; 14:775.</a></li><li><a class="nounderline abstract_t">Toze CL, Barnett MJ, Connors JM, et al. Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol 2004; 127:311.</a></li><li><a class="nounderline abstract_t">Khouri IF, Keating M, Körbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16:2817.</a></li><li><a class="nounderline abstract_t">Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98:3595.</a></li><li><a class="nounderline abstract_t">Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100:4310.</a></li><li><a class="nounderline abstract_t">Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004; 103:428.</a></li><li><a class="nounderline abstract_t">Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104:3865.</a></li><li><a class="nounderline abstract_t">de Lavallade H, Mohty M, El-Cheikh J, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma. Br J Haematol 2006; 135:408.</a></li><li><a class="nounderline abstract_t">Thomson KJ, Morris EC, Milligan D, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010; 28:3695.</a></li><li><a class="nounderline abstract_t">Piñana JL, Martino R, Gayoso J, et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 2010; 95:1176.</a></li><li><a class="nounderline abstract_t">Abou-Nassar KE, Stevenson KE, Antin JH, et al. (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant 2011; 46:1503.</a></li><li><a class="nounderline abstract_t">Shea T, Johnson J, Westervelt P, et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 2011; 17:1395.</a></li><li><a class="nounderline abstract_t">Khouri IF, Milton DR, Gulbis AM, et al. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clin Cancer Res 2021; 27:5847.</a></li><li><a class="nounderline abstract_t">Khouri IF, Saliba RM, Erwin WD, et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 2012; 119:6373.</a></li><li><a class="nounderline abstract_t">Evens AM, Vanderplas A, LaCasece AS, et al. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project (in press). Cancer 2013.</a></li><li><a class="nounderline abstract_t">van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102:3521.</a></li><li><a class="nounderline abstract_t">Avivi I, Montoto S, Canals C, et al. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2009; 147:719.</a></li><li><a class="nounderline abstract_t">Mandigers CM, Verdonck LF, Meijerink JP, et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003; 32:1159.</a></li><li><a class="nounderline abstract_t">van Besien KW, de Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19:977.</a></li><li><a class="nounderline abstract_t">Bloor AJ, Thomson K, Chowdhry N, et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14:50.</a></li></ol></div><div id="topicVersionRevision">Topic 88808 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29424927" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18215784" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410896" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17162215" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17916744" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20114084" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7738615" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16522821" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18318762" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23401459" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18411419" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056679" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342784" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18541196" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15491292" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704734" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739162" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393626" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12969983" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304395" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16978221" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20606089" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20107156" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258420" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21296675" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34380640" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22586182" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project (in press)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12893748" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19793383" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14647270" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9169641" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18158961" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
